The diagnostic biomarker problem in amyotrophic lateral sclerosis

Clicks: 26
ID: 328964
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #106 of 456 articles by views in Brain research

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 456 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In the effort to reduce the long diagnostic delay in amyotrophic lateral sclerosis, an often overlooked problem derives from confusion around the concept of diagnostic biomarkers and the type of data required to develop such tools. A useful diagnostic biomarker is one that can correctly differentiate individuals with, from those without, the disease of interest - and importantly, at a point in time when the diagnosis is otherwise uncertain. This requires a test with a high positive predictive value (the proportion of positive test results that are true positives), a high negative predictive value (the proportion of negative test results that are true negatives), or ideally both. Critically, positive and negative predictive values depend on the context of use for the diagnostic, which determines the prevalence of disease in the population in which the diagnostic test will be used. Almost all diagnostic biomarker studies in amyotrophic lateral sclerosis get this wrong - focusing on data and samples from patients for whom there is no diagnostic uncertainty. This Update distinguishes disease state biomarkers from diagnostic biomarkers; highlights the data required to clinically validate a diagnostic biomarker; underscores the critical importance of understanding the clinical context in which the diagnostic biomarker will be used; and outlines potential strategies for developing diagnostic biomarkers that might be clinically useful.
Reference Key
openalex_W7213243663 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Michael Benatar, Joanne Wuu, Martin R. Turner, Eric A. Macklin
Are you one of these authors? Claim your profile
Journal Brain research
Year 2026
DOI
10.1093/brain/awag313
URL
https://doi.org/10.1093/brain/awag313
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.